We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
- Authors
Singer, Barry A.; Feng, Jenny; Chiong-Rivero, Horacio
- Abstract
Multiple sclerosis (MS) is characterized by progressive neuroinflammation and neurodegeneration from disease onset that, if left untreated, can result in the accumulation of irreversible neurological disability. Early intervention with high-efficacy therapies (HETs) is increasingly recognized as the best strategy to delay or mitigate disease progression from the earliest stages of the disease and to prevent long-term neurodegeneration. Although there is growing clinical and real-world evidence supporting early HET intervention, foregoing this strategy in favor of a traditional escalation approach prioritizing lower-efficacy disease-modifying therapies remains a common approach in clinical practice. This review explores potential health care professional- and patient-related barriers to the early use of HETs in patients with MS in the United States. Barriers can include regulatory and reimbursement restrictions; knowledge gaps and long-term safety concerns among health care professionals; and various individual, cultural, and societal factors affecting patients. Potential strategies for overcoming these barriers and encouraging early HET use are proposed.
- Subjects
UNITED States; MEDICAL personnel; MULTIPLE sclerosis; MEDICAL care; DISEASE progression
- Publication
Journal of Neurology, 2024, Vol 271, Issue 6, p3116
- ISSN
0340-5354
- Publication type
Article
- DOI
10.1007/s00415-024-12305-4